Major biopharma companies are partnering with pioneers of genome-editing technologies to realize the potential of this emerging precision medicine modality.

The commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.

In conversation with Hiroyuki Sonoda, VP, Research & Corporate Strategy Executive Director, Research Division, JCR Pharmaceuticals

Approaches to slow or reverse aging have gained momentum in recent years, but the field is still in its infancy with hurdles to overcome, as illustrated by efforts to develop therapies that clear senescent cells.

Vasomune Therapeutics has brought together decades of academic research to create a clinical-stage candidate for the treatment of diseases associated with vascular dysfunction, particularly pathogen-induced acute respiratory-distress syndrome.

By coupling its expertise, scale, and technologies with those of like-minded biopharma partners GSK is striving to make a real difference for patients.

The government-funded Korea Drug Development Fund (KDDF) is investing in companies developing next-generation anticancer drugs.

Genialis is the RNA biomarker company; it espouses a people-first approach to machine learning–driven biomarker discovery. For targeted therapies to benefit the most patients possible, Genialis develops predictive biomarkers to guide treatment decisions. The company’s next-generation biomarkers work for real patients by informing targeted treatment decisions for better outcomes.

MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.

Algen Biotechnologies’ unique functional genomics technologies tease apart complex disease biology using human-centric therapeutic endpoints to identify novel targets and best-in-class molecules.

The commercial success of second-generation radiopharmaceuticals in oncology has re-ignited interest in this modality, resulting in a surge of dealmaking and increased venture financing for companies in the field.

Major biopharma companies are partnering with pioneers of genome-editing technologies to realize the potential of this emerging precision medicine modality.

CRISPR QC’s chip platform-enabling efficiency that aims to power the next generation of CRISPR therapies.